NMTC NeuroOne Medical Technologies |
$0.83
+1.2% |
-2.4%
 |
OneRF
Ablation System for creation of radiofrequency ("RF") lesions in nervous tissue for functional neurosurgical procedures.
|
|
8/18/2025 - FDA Clearance
NeuroOne Medical Technologies Corporation announced that it has received U.S. Food and Drug Adminis…
Full Summary
|
LH Labcorp |
$270.87
+0.2% |
+11.1%
 |
Lumipulse®
Blood Test for Alzheimer's Disease
|
|
8/18/2025 - Provided Update
Labcorp announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first…
Full Summary
|
RDY Dr. Reddy's Laboratories |
$14.26
+0.2% |
-1.6%
 |
Carac
For the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
|
|
8/18/2025 - Launch
Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy's …
Full Summary
|
PSTV Plus Therapeutics |
$0.54
-14.6% |
+44.3%
 |
REYOBIQ™
For Patients with Leptomeningeal Metastases
|
Phase 1
|
8/18/2025 - Positive Data
Plus Therapeutics, Inc. announces positive data from the ReSPECT-LM Phase 1 single dose escalation …
Full Summary
|
VNDA Vanda Pharmaceuticals |
$4.56
+4.6% |
-4.6%
 |
HETLIOZ
For treat jet lag disorder
|
|
8/18/2025 - Regulatory Update
Vanda Pharmaceuticals Inc. announced that it secured a landmark victory over the U.S. Food and Drug…
Full Summary
|
NTRA Natera |
$161.15
-1.1% |
+16.0%
 |
IMvigor011
in Muscle-Invasive Bladder Cancer
|
Phase 3
|
8/18/2025 - Positive Results
Natera, Inc. announced positive topline results from the randomized, phase III IMvigor011 clinical t…
Full Summary
|
MMSI Merit Medical Systems |
$86.16
+0.8% |
+3.8%
 |
WRAPSODY
Cell-Impermeable Endoprosthesis (CIE).
|
|
8/18/2025 - Enrollment Update
Merit Medical Systems announced today the successful enrollment of the first patient in the WRAP Nor…
Full Summary
|
PFE Pfizer |
$25.07
-0.3% |
+2.5%
 |
PAXLOVID
Covid-19
|
Phase 2
|
8/18/2025 - evaluation
Traws Pharma, Inc. announced receipt from the Human Research Ethics Committee (HREC) of approval to…
Full Summary
|
BTAI BioXcel Therapeutics |
$5.67
+3.5% |
+196.9%
 |
BXCL501 (SERENITY)
Schizophrenia and bipolar disorders
|
supplemental New Drug Application (sNDA)
|
8/18/2025 - Positive Opinion
BioXcel Therapeutics, announced that it has received positive pre-sNDA meeting responses from the U…
Full Summary
|
MRK Merck & Co., Inc. |
$84.21
|
+5.3%
 |
I-DXd
In patients with pretreated extensive-stage small cell lung cancer (ES-SCLC).
|
Breakthrough Therapy
|
8/18/2025 - Designation Grant
Daiichi Sankyo and Merck announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough…
Full Summary
|
BMY Bristol Myers Squibb |
$48.19
-0.5% |
+1.7%
 |
iza-bren
For Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
|
Breakthrough Therapy
|
8/18/2025 - Designation Grant
SystImmune Inc. and Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA)…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$29.70
+0.0% |
+12.9%
 |
DTX401 AAV
For the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
|
BLA
|
8/18/2025 - rolling submission
Ultragenyx Pharmaceutical announced the initiation of a rolling submission of a Biologics License A…
Full Summary
|
ENLV Enlivex Therapeutics |
$1.25
-31.3% |
+5.0%
 |
Allocetra
Sepsis
|
|
8/18/2025 - Top-line results
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial…
Full Summary
|
BTAI BioXcel Therapeutics |
$5.67
+3.5% |
+196.9%
|
BXCL501 (SERENITY)
Schizophrenia and bipolar disorders
|
supplemental New Drug Application (sNDA)
Target date: Q1 2026
|
8/18/2025 - sNDA Filing
BioXcel Therapeutics, announced that sNDA submission on track for Q1 2026
Full Summary
|
RGNX REGENXBIO |
$8.71
-1.2% |
+6.7%
 |
RGX-121
MPS II (Hunter Syndrome)
|
BLA
|
8/18/2025 - Provided Update
REGENXBIO Inc. announced that the U.S. Food and Drug Administration (FDA) extended its review timeli…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$29.70
+0.0% |
+12.9%
|
DTX401 AAV
For the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
|
BLA
Target date: Q4 2025
|
8/18/2025 - BLA Filing
Ultragenyx Pharmaceutical announced that company has submitted the non-clinical and clinical modules…
Full Summary
|
CAPR Capricor Therapeutics |
$7.70
-3.3% |
+11.9%
 |
StealthX
exosome-based vaccine.
|
Phase 1
|
8/18/2025 - Dose Update
Capricor Therapeutics announced that the first subjects have been dosed in a Phase 1 clinical trial…
Full Summary
|
IRD Opus Genetics |
$1.15
-4.2% |
+1.8%
 |
OPGx-BEST1
For the treatment of bestrophin-1 (BEST1)-related IRD.
|
IND
|
8/18/2025 - FDA Accepted
Opus Genetics announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigat…
Full Summary
|
SVRA Savara |
$3.05
+0.3% |
+35.0%
 |
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
8/18/2025 - FDA Accepted
Savara Inc announced the acceptance of three abstracts for poster presentation at the European Resp…
Full Summary
|
IOVA Iovance Biotherapeutics |
$2.50
-2.0% |
+12.1%
 |
Lifileucel
For the Treatment of Advanced Melanoma
|
|
8/18/2025 - Notice of Compliance
Iovance Biotherapeutics, announced Health Canada has issued a Notice of Compliance with Conditions …
Full Summary
|
AAPG Ascentage Pharma Group International |
$47.49
+5.6% |
+17.6%
 |
lisaftoclax
In Venetoclax-Refractory Patients
|
|
8/17/2025 - FDA Clearance
Ascentage Pharma announced that it has received clearance by the U.S. Food and Drug Administration …
Full Summary
|
GBT Global Blood Therapeutics |
$68.49
|
|
Inclacumab + GBT601
Sickle Cell Disease
|
Phase 3
|
8/15/2025 - Results
Pfizer Inc announced results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigati…
Full Summary
|
PGEN Precigen |
$2.95
+0.3% |
+67.6%
 |
PAPZIMEOS
For Treatment Of Adults With Recurrent Respiratory Papillomatosis
|
|
8/15/2025 - FDA approved
Precigen, Inc. announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS™ (zo…
Full Summary
|
TNXP Tonix Pharmaceuticals |
$40.07
-22.0% |
-14.6%
 |
Tonmya
For the management of fibromyalgia.
|
|
8/15/2025 - FDA approved
Tonix Pharmaceuticals Holding Corp announced that the U.S. Food and Drug Administration (FDA) appro…
Full Summary
|
BIOA BioAge Labs |
$4.52
-0.7% |
-2.4%
 |
BGE-102
For the treatment of obesity.
|
Phase 1
|
8/15/2025 - Dose Update
BioAge Labs, Inc. announced that the first participant has been dosed in a Phase 1 clinical trial ev…
Full Summary
|
VERU Veru |
$3.51
-2.2% |
-41.2%
 |
Wegovy
For cardiovascular risk reduction in adults with known heart disease and overweight or obesity
|
|
8/15/2025 - FDA approved
Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved a new indication …
Full Summary
|
NVO Novo Nordisk A/S |
$53.81
+2.7% |
-16.3%
 |
Wegovy
For cardiovascular risk reduction in adults with known heart disease and overweight or obesity
|
|
8/15/2025 - FDA approved
Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved a new indication …
Full Summary
|
SRRK Scholar Rock |
$31.52
+0.4% |
-22.6%
 |
Apitegromab
Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
|
|
8/14/2025 - Published Results
Scholar Rock announced that positive study results from the pivotal Phase 3 SAPPHIRE trial (NCT05156…
Full Summary
|
TLSA Tiziana Life Sciences |
$1.89
-4.1% |
+21.9%
 |
Foralumab
Crohn's disease with decreases in the classic side effects of cytokine release syndrome
|
Phase 2a
|
8/14/2025 - Enrollment Update
Tiziana Life Sciences, Ltd. announced that the first participant has been enrolled and dosed in its…
Full Summary
|
ATHA Athira Pharma |
$0.39
-1.9% |
-3.7%
 |
ATH-1105
For Amyotrophic Lateral Sclerosis
|
Phase 1
|
8/14/2025 - presented results
Athira Pharma, Inc. presented results from its Phase 1 clinical trial of ATH-1105 in healthy volunte…
Full Summary
|
TRIB Trinity Biotech |
$1.57
-3.1% |
+115.4%
 |
PreClara
Preeclampsia Testing Service
|
Target date: Q3 2025
|
8/14/2025 - Regulatory Update
Trinity Biotech plc announced that this week its New York, reference laboratory has received regula…
Full Summary
|
SMMT Summit Therapeutics |
$26.29
-1.5% |
+0.3%
 |
Ivonescimab
For Lung cancer
|
Phase 3
|
8/14/2025 - Data
Summit Therapeutics Inc. announced that data from the Phase III HARMONi trial featuring the novel, …
Full Summary
|
BEAM Beam Therapeutics |
$17.10
-4.0% |
-17.6%
 |
BEAM-101
Sickle cell diseas
|
RMAT Designation
|
8/14/2025 - Designation Grant
Beam Therapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) …
Full Summary
|
ENLV Enlivex Therapeutics |
$1.25
-31.3% |
+5.0%
|
Allocetra
Sepsis
|
Phase 2a
|
8/14/2025 - Presentation
Enlivex Therapeutics Ltd. announced it will host a webinar on Monday, August 18, 2025, at 8:00 AM …
Full Summary
|
AKRO Akero Therapeutics |
$48.59
-1.6% |
-6.7%
 |
Efruxifermin (HARMONY)
Non-alcoholic steatohepatitis (NASH)
|
|
8/14/2025 - Publication
Akero Therapeutics, Inc. announced publication of 96-week results from the Phase 2b HARMONY trial i…
Full Summary
|
MRK Merck & Co., Inc. |
$84.21
|
+5.3%
|
KEYNOTE-689
In Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Health Canada Approval
|
8/13/2025 - Approved
Merck announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck'…
Full Summary
|
OCGN Ocugen |
$1.04
-1.0% |
+2.0%
 |
OCU410ST
For Stargardt Disease
|
EMA
|
8/13/2025 - review
Ocugen, Inc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…
Full Summary
|
CTMX CytomX Therapeutics |
$2.12
+11.0% |
-10.9%
 |
CX-2051
A Probody® Antibody Drug Conjugate (ADC)
|
Phase 1
|
8/13/2025 - Provided Update
CytomX Therapeutics, Inc provided an update on the CX-2051 Phase 1 study to address certain recent…
Full Summary
|
NUVL Nuvalent |
$75.01
-1.4% |
-10.1%
 |
zidesamtinib
ALK-selective inhibitor, neladalkib, and novel ROS1-selective inhibitor, zidesamtinib
|
Phase 1/2
|
8/13/2025 - Data
Nuvalent, Inc. announced that pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TK…
Full Summary
|
MDWD MediWound |
$17.60
-2.8% |
-14.0%
 |
EscharEx
Chronic Wounds
|
|
8/13/2025 - Publication
MediWound Ltd. announced the publication of "The Correlation Between Wound Bed Preparation and Woun…
Full Summary
|
INVA Innoviva |
$20.78
-0.7% |
+6.2%
 |
XACDURO®
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use is a combination of sulbactam, a beta-lactam antibacterial, and durlobactam, a beta-lactamase inhibitor
|
|
8/13/2025 - Provided Update
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. announced that two of the company's…
Full Summary
|
GLSI Greenwich LifeSciences |
$12.01
-1.3% |
+3.6%
 |
GLSI-100
Breast cancer recurrences
|
|
8/13/2025 - Provided Update
Greenwich LifeSciences, Inc. announced the addition of clinical sites in Romania.
Full Summary
|
ALGS Aligos Therapeutics |
$8.77
+13.9% |
-4.3%
 |
ALG-000184
Hepatitis B
|
Phase 2b
|
8/13/2025 - Dose Update
Aligos Therapeutics, Inc. announced that dosing in the Phase 2 B-SUPREME study of its investigationa…
Full Summary
|
PRTC PureTech Health |
$19.84
+10.2% |
+4.1%
 |
VE202
Inflammatory Bowel Disease
|
Phase 2
|
8/13/2025 - Endpoint Missed
PureTech Health plc announced that its candidate VE202 did not meet the primary endpoint in the Pha…
Full Summary
|
CGTX Cognition Therapeutics |
$1.49
-3.2% |
+127.8%
 |
CT1812
Designed to penetrate the blood-retinal barrier and bind selectively and saturably to the σ-2 receptor complex.
|
Phase 2
|
8/12/2025 - Meeting minutes
Cognition Therapeutics, announced that it has received final minutes from the U.S. Food and Drug A…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.48
-1.3% |
-17.8%
 |
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
|
|
8/12/2025 - Provided Update
MIRA Pharmaceuticals announced the acceptance of a second peer-reviewed manuscript describing its le…
Full Summary
|
OCUL Ocular Therapeutix |
$12.31
-2.5% |
+8.6%
 |
AXPAXLI
In Diabetic Retinopathy
|
|
8/12/2025 - Provided Update
Ocular Therapeutix, Inc. announced it has received written agreement regarding a registrational tri…
Full Summary
|
INSM Insmed |
$127.27
-0.4% |
+24.1%
 |
Brensocatib
In Patients with Bronchiectasis
|
|
8/12/2025 - FDA approved
Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved first-i…
Full Summary
|
AARD Aardvark Therapeutics |
$10.44
-3.2% |
-10.2%
 |
ARD-201
For the treatment of metabolic obesity and obesity-related conditions.
|
|
8/12/2025 - Positive Data
Aardvark Therapeutics, Inc. announced new positive preclinical data demonstrating the potential of …
Full Summary
|
IOBT IO Biotech |
$2.09
-3.2% |
+2.0%
 |
Cylembio
For the Treatment of First-line Advanced Melanoma
|
Phase 3
|
8/11/2025 - Top-line results
IO Biotech announces topline results from the pivotal Phase 3 trial of its investigational, immune-m…
Full Summary
|
STOK Stoke Therapeutics |
$18.51
+1.6% |
+40.0%
 |
zorevunersen
For the treatment of Dravet syndrome with a confirmed mutation,
|
Phase 3
|
8/11/2025 - Dosing Update
Stoke Therapeutics, Inc announced that the first patient has been dosed in the global Phase 3 EMPER…
Full Summary
|
QNTM Quantum Biopharma |
$20.61
-8.2% |
-11.8%
 |
Lucid-MS
For people to gain back mobility lost with multiple sclerosis (MS).
|
|
8/11/2025 - Provided Update
Quantum BioPharma Ltd. announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that i…
Full Summary
|
NVS Novartis |
$123.96
-0.2% |
+8.5%
 |
ianalumab
In adults with active Sjögren's disease.
|
Phase 3
|
8/11/2025 - Top-line results
Novartis announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736)…
Full Summary
|
IMAB I-Mab |
$5.09
+4.5% |
+142.4%
 |
Givastomig
In patients with advanced cancers
|
Phase 1b
|
8/11/2025 - Enrollment Update
I-Mab announced that enrollment in the planned Phase 1b dose expansion cohorts evaluating givastomi…
Full Summary
|
NRXP NRx Pharmaceuticals |
$2.76
-4.5% |
-6.1%
 |
NRX-100
To treat acute depression and suicidality
|
Fast Track
|
8/11/2025 - Designation Grant
NRx Pharmaceuticals, Inc. announced US Food and Drug Administration (FDA) has granted Fast Track de…
Full Summary
|
TLSA Tiziana Life Sciences |
$1.89
-4.1% |
+21.9%
|
Foralumab
Crohn's disease with decreases in the classic side effects of cytokine release syndrome
|
IND
|
8/11/2025 - FDA approved
Tiziana Life Sciences, Ltd. is pleased to announce that the U.S. Food & Drug Administration (FDA) h…
Full Summary
|
NVCT Nuvectis Pharma |
$6.45
+0.3% |
-17.3%
 |
NXP900
Novel inhibitor of the SRC family of kinases
|
Phase 1b
|
8/11/2025 - Provided Update
Nuvectis Pharma, Inc. announced the initiation of the Phase 1b program for NXP900.
Full Summary
|
INO Inovio Pharmaceuticals |
$1.90
+2.2% |
+36.7%
 |
INO-3107
For the Treatment of Recurrent Respiratory Papillomatosis
|
|
8/11/2025 - Peer-reviewed data
INOVIO nnounced that peer-reviewed data from a retrospective study investigating the long-term clini…
Full Summary
|
AMPH Amphastar Pharmaceuticals |
$29.76
-0.2% |
+44.3%
 |
Venofer
In patients with chronic kidney disease (CKD).
|
|
8/11/2025 - FDA approved
Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration ("FDA") has ap…
Full Summary
|
MRK Merck & Co., Inc. |
$84.21
|
+5.3%
|
EV-303
For Certain Patients with Muscle-Invasive Bladder Cancer
|
Phase 3
|
8/11/2025 - Top-line results
Merck announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) i…
Full Summary
|
IXHL Incannex Healthcare |
$0.40
+5.2% |
-34.4%
 |
IHL-42X
Obstructive Sleep Apnoea (OSA)
|
Phase 2
|
8/8/2025 - Findings Update
Incannex Healthcare Inc announced new patient-reported outcome findings from a subset of participant…
Full Summary
|
CAPR Capricor Therapeutics |
$7.70
-3.3% |
+11.9%
|
deramiocel
For the treatment of Duchenne muscular dystrophy (DMD)
|
Type A Meeting
|
8/8/2025 - FDA Meeting
Capricor Therapeutics announced that a Type A meeting with the U.S. Food and Drug Administration (…
Full Summary
|
OBIO Orchestra BioMed |
$2.63
+2.3% |
-14.9%
 |
BACKBEAT
AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications.
|
|
8/8/2025 - FDA approved
Orchestra BioMed Holdings, announced the roll out of a protocol update, approved by the U.S. Food …
Full Summary
|
ASMB Assembly Biosciences |
$25.76
+1.3% |
+37.9%
 |
ABI-5366
For recurrent genital herpes.
|
|
8/8/2025 - Positive Results
Assembly Biosciences, Inc announced positive interim antiviral activity, clinical outcomes, safety …
Full Summary
|
ARVN Arvinas |
$7.17
+1.1% |
-2.4%
 |
Vepdegestrant
For ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
|
NDA
Target date: June 05, 2026
|
8/8/2025 - PDUFA Date
Arvinas, Inc. announced that The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action d…
Full Summary
|
ARVN Arvinas |
$7.17
+1.1% |
-2.4%
|
Vepdegestrant
For ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
|
NDA
|
8/8/2025 - FDA Accepted
Arvinas, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug A…
Full Summary
|
NYXH Nyxoah |
$6.57
+5.6% |
-20.1%
 |
Genio
For the Treatment of Obstructive Sleep Apnea
|
|
8/8/2025 - FDA approved
Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system f…
Full Summary
|
FGEN FibroGen |
$11.30
+19.1% |
+47.7%
 |
roxadustat
Anemia of chronic kidney disease (CKD)
|
Target date: Q4 2025
|
8/7/2025 - Provided Update
FibroGen announced that Company intends to file the Phase 3 protocol in the fourth quarter of 2025
Full Summary
|
FGEN FibroGen |
$11.30
+19.1% |
+47.7%
|
roxadustat
Anemia of chronic kidney disease (CKD)
|
FDA Type C Meeting
|
8/7/2025 - Positive Feedback
FibroGen announced positive feedback from its Type C meeting with the FDA, supporting the advanceme…
Full Summary
|
LLY Eli Lilly and Company |
$698.89
-0.3% |
-9.4%
 |
orforglipron
Orforglipron for the treatment of obesity and overweight
|
Phase 3
|
8/7/2025 - Top-line results
Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluatin…
Full Summary
|
SLS SELLAS Life Sciences Group |
$1.73
+6.1% |
-2.3%
 |
galinpepimut-S (GPS)
Targets the WT1 protein, which is present in an array of tumor types.
|
Phase 3
|
8/7/2025 - Analysis
SELLAS Life Sciences Group, Inc. announced that the Independent Data Monitoring Committee (IDMC) ha…
Full Summary
|
VTVT vTv Therapeutics |
$15.48
+0.2% |
-7.7%
 |
Cadisegliatin
For Type 1 Diabetes
|
Phase 3
|
8/7/2025 - Provided Update
vTv Therapeutics Inc. announced the first study participant has been randomized in the Company's CA…
Full Summary
|
GLPG Galapagos |
$32.91
+1.4% |
+5.7%
 |
GLPG5101
In patients with relapsed/refractory chronic lymphocytic leukemia
|
RMAT Designation
|
8/6/2025 - Designation Grant
Galapagos NV announced that the United States Food and Drug Administration (FDA) has granted RMAT de…
Full Summary
|
MAT Mattel |
$17.95
-1.3% |
-7.4%
 |
Barbie
type 1 diabetes (T1D)
|
|
8/6/2025 - Provided Update
Mattel, Inc announced a partnership between its iconic Barbie™ brand and Quo Beauty®, the beloved an…
Full Summary
|
DTIL Precision BioSciences |
$4.95
+5.1% |
+7.4%
 |
PBGENE-HBV
For chronic hepatitis B virus (HBV)
|
|
8/6/2025 - Results
Precision BioSciences, Inc announced ELIMINATE-B results as of the data cutoff of July 28, 2025.
Full Summary
|
TEVA Teva Pharmaceutical Industries |
$18.08
+1.2% |
+12.4%
 |
AJOVY (Fremanezumab-vfrm)
Comorbid depression, anxiety or hypertension, as well as migraine
|
|
8/6/2025 - FDA approved
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced that the U.S…
Full Summary
|
LNTH Lantheus |
$55.97
+3.3% |
-20.2%
 |
Piflufolastat F 18 (formerly 8F-DCFPyL)
Biochemically Recurrent Prostate Cancer (CONDOR)
|
NDA
Target date: March 06, 2026
|
8/6/2025 - PDUFA Date
Lantheus Holdings, announced that The FDA has set an action date goal of March 6, 2026 under the Pr…
Full Summary
|
LTRN Lantern Pharma |
$4.44
-2.8% |
+11.3%
 |
LP-184
Prostate cancer
|
IND
|
8/6/2025 - FDA Clearance
Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. announced that the U.S. Fo…
Full Summary
|
ACTU Actuate Therapeutics |
$8.25
+1.6% |
+43.2%
 |
elraglusib
In relapsed/refractory Ewing Sarcoma (r/r EWS).
|
Phase 1b
|
8/6/2025 - Trial Initiation
Actuate Therapeutics, Inc. announced the initiation of the Phase 1b trial of elraglusib in combinati…
Full Summary
|
LNTH Lantheus |
$55.97
+3.3% |
-20.2%
|
Piflufolastat F 18 (formerly 8F-DCFPyL)
Biochemically Recurrent Prostate Cancer (CONDOR)
|
NDA
|
8/6/2025 - FDA Accepted
Lantheus Holdings, announced that the Food and Drug Administration (FDA) has accepted a New Drug App…
Full Summary
|
RNXT RenovoRx |
$0.94
-1.6% |
-27.7%
 |
RenovoCath
Solid Tumors
|
|
8/6/2025 - Provided Update
RenovoRx, Inc. announced strong progress in its commercialization efforts, including its growing cus…
Full Summary
|
IMMX Immix Biopharma |
$2.30
+1.3% |
-22.6%
 |
NXC-201
NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.
|
|
8/6/2025 - Provided Update
Immix Biopharma, Inc. announced important updates about its plan to address other serious diseases…
Full Summary
|
ICU SeaStar Medical |
$0.83
+3.2% |
+16.9%
 |
NEUTRALIZE-AKI
In adults with acute kidney injury
|
|
8/6/2025 - Enrollment Plan
SeaStar Medical Holding announced that it has successfully reached enrollment of 125 patients in the…
Full Summary
|
BTAI BioXcel Therapeutics |
$5.67
+3.5% |
+196.9%
|
BXCL501 (dexmedetomidine)
For dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist
|
|
8/6/2025 - Publication
BioXcel Therapeutics announced a publication in the peer-reviewed journal Frontiers in Pharmacology…
Full Summary
|
KROS Keros Therapeutics |
$14.52
+0.3% |
+5.6%
 |
KER-065
To treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins
|
|
8/6/2025 - Provided Update
Keros Therapeutics, Inc. announced a strategic realignment designed to reallocate resources towards…
Full Summary
|
MBRX Moleculin Biotech |
$0.61
-10.6% |
-23.9%
 |
Annamycin
Soft tissue sarcoma (STS) lung metastases
|
|
8/6/2025 - Presentation
Moleculin Biotech, Inc., announced the presentation of encouraging preclinical data for its lead dr…
Full Summary
|
CMRX Chimerix |
$8.54
|
|
dordaviprone
treatment for recurrent H3 K27M-mutant diffuse glioma
|
|
8/6/2025 - FDA GRANT
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted acc…
Full Summary
|
CING Cingulate |
$4.16
+3.0% |
-19.5%
 |
CTx-1301
Attention Deficit/Hyperactivity Disorder (ADHD)
|
|
8/6/2025 - NDA Filing
Cingulate announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug …
Full Summary
|
JAZZ Jazz Pharmaceuticals |
$117.67
-0.1% |
+4.3%
 |
dordaviprone
treatment for recurrent H3 K27M-mutant diffuse glioma
|
|
8/6/2025 - FDA GRANT
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted acc…
Full Summary
|
IMMP Prima BioMed |
$1.78
+2.9% |
+4.7%
 |
eftilagimod alpha
For cancer and autoimmune disease
|
|
8/5/2025 - Positive Feedback
Immutep Limited announces it has received positive and constructive feedback from the US Food and D…
Full Summary
|
COCP Cocrystal Pharma |
$1.56
-8.0% |
-4.9%
 |
CDI-988
For Pandemic Norovirus and Coronavirus
|
Phase 1
|
8/5/2025 - Presentation
Cocrystal Pharma, announces the presentation of favorable safety and tolerability data from a random…
Full Summary
|
NUVB Nuvation Bio |
$2.90
+5.5% |
+25.5%
 |
IBTROZI
In Advanced ROS1-Positive Non-Small Cell Lung Cancer
|
|
8/5/2025 - Data Presentation
Nuvation Bio Inc announced that new data will be presented at the IASLC 2025 World Conference on Lun…
Full Summary
|
URGN Urogen Pharma |
$19.40
-1.6% |
+27.0%
 |
ZUSDURI
for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
|
|
8/5/2025 - Provided Update
UroGen Pharma announced the 24-month DOR of 72.2% (95% CI 64.1%, 78.8%) by Kaplan-Meier estimate in…
Full Summary
|
DYN Dyne Therapeutics |
$12.33
-0.4% |
+36.7%
 |
DYNE-251
Duchenne Muscular Dystrophy
|
BLA
|
8/4/2025 - BLA Filing
Dyne Therapeutics, Inc announced that potential BLA submission for U.S. accelerated approval anticip…
Full Summary
|
INMB INmune Bio |
$2.53
|
+4.5%
 |
INKmune
High-Risk Myelodysplastic Syndrome (MDS)
|
Phase 1/2
|
8/4/2025 - Provided Update
INmune Bio Inc. is pleased to report that its Phase I/II trial (the "CaRe PC" trial) of INKmune™ fo…
Full Summary
|
BCDA BioCardia |
$1.88
-2.1% |
-15.7%
 |
CardiAMP
Designed to be a comprehensive biotherapeutic heart failure solution
|
|
8/4/2025 - Regulatory Update
BioCardia®, today provides the anticipated timing of regulatory activities seeking FDA and Japan PM…
Full Summary
|
SAVA Cassava Sciences |
$2.27
-3.0% |
+2.7%
 |
Simufilam
Alzheimer's Disease
|
Target date: H1 2026
|
8/4/2025 - Clinical Study
Cassava Sciences, Inc. announced that First clinical study for simufilam in TSC-related epilepsy ex…
Full Summary
|
AIMD Ainos |
$3.35
-3.2% |
+20.9%
 |
VELDONA
Potential Treatment of Oral Warts in HIV-Seropositive
|
Taiwan's Food and Drug Administration (TFDA)
|
8/4/2025 - Approved
Ainos, Inc. announced that its investigational low-dose oral interferon-alpha drug candidate, VELDO…
Full Summary
|
SONN Sonnet BioTherapeutics |
$3.35
-5.4% |
-45.8%
 |
SON-1010
Advanced Solid Tumors
|
|
8/4/2025 - Clinical Study
Sonnet BioTherapeutics announced the expansion of its clinical study of patients with platinum-resi…
Full Summary
|
TMDX TransMedics Group |
$125.65
-1.5% |
+14.4%
 |
OCS™ Heart System
For patients with end-stage lung, heart, and liver failure
|
Investigational Device Exemption
|
8/4/2025 - Conditional approval
TransMedics Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted cond…
Full Summary
|
MarketBeat All Access